by Truveta Research | Jul 8, 2024 | Research
Truveta Research’s comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro) has been published in JAMA Internal Medicine. Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications,...
by Truveta Research | Nov 27, 2023 | Research, Research Insights
Today Truveta announced new comparative effectiveness research exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro). Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1...
by Truveta Research | Jun 6, 2023 | Research, Research Insights
Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have taken to TikTok to promote GLP-1s for weight loss, and celebrities & influencers – such...
